Below the waterline -- the danger of de novo donor-specific HLA antibodies
- PMID: 22537262
- PMCID: PMC3728658
- DOI: 10.1111/j.1600-6143.2012.04016.x
Below the waterline -- the danger of de novo donor-specific HLA antibodies
Conflict of interest statement
The authors of this manuscript have no conflicts of interest to disclose as described by the
Comment on
-
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.Am J Transplant. 2012 May;12(5):1157-67. doi: 10.1111/j.1600-6143.2012.04013.x. Epub 2012 Mar 19. Am J Transplant. 2012. PMID: 22429309 Clinical Trial.
References
-
- Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival improvement in the United States: The long-term does not mirror the dramatic short-term success. Am J Transplant. 2011;11:1226–1235. - PubMed
-
- Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157–1167. - PubMed
-
- Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA) Am J Transplant. 2011;11:56–65. - PubMed
-
- Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Human Immunol. 2011;72:849–858. - PubMed
-
- Honger G, Hopfer H, Arnold ML, Spriewald BM, Schaub S, Amico P. Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation. 2011;92:41–47. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
